Despite these benefits, inevitably acquired mutations during osimertinib therapy, such as the C797S mutation,26 as well as the interpatient, intratumoral, and intertumoral heterogeneity of NSCLC,27 complicate the optimal therapeutic determination of EGFR‐TKI sequence. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.